Tourmaline Bio, Inc.
TRML · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $514,057 | $124,276 | $207,435 | $1,662,788 |
| - Cash | $30,506 | $140,726 | $8,258 | $18,614 |
| + Debt | $244 | $415 | $504 | $150 |
| Enterprise Value | $483,795 | -$16,035 | $199,681 | $1,644,324 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$39 | -$33 | -$6 | -$623 |
| % Margin | – | – | – | – |
| EBITDA | -$89,732 | -$42,091 | -$19,695 | -$46,884 |
| % Margin | – | – | – | – |
| Net Income | -$73,210 | -$42,124 | -$19,701 | -$1 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.89 | -8.87 | -0.97 | -0 |
| % Growth | 67.4% | -814.4% | -969,900% | – |
| Operating Cash Flow | -$77,263 | -$28,081 | -$6,458 | -$39,988 |
| Capital Expenditures | -$9 | -$56 | -$5,068 | -$2,437 |
| Free Cash Flow | -$77,272 | -$28,137 | -$11,526 | -$42,425 |